AB Science has received a patent in Japan covering the use of its investigational oral therapy masitinib for progressive forms of multiple sclerosis (MS). The new patent — JP 7788154 — grants the France-based pharmaceutical company protection in the Asian nation through February 2041 on the use of masitinib for both primary progressive MS (PPMS) and nonactive secondary […]
The post Developer granted patent in Japan for masitinib use in progressive MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com